Hanley et al. [22] identified NOX4 as a critical regulator of myCAF activation in multiple tumour types, including HNSCC, and found that inhibiting NOX4 using Setanaxib (GKT137831), a drug developed to treat organ fibrosis, suppressed myCAF activation and also “normalized” established myCAF. This evidence concerns the gene NOX4 and head and neck squamous cell carcinoma.